RxDoctor Payments Data

Colin McLeod, MD

Neurology · Augusta, GANPI 1750720124

Payments from drug & device makers

$48,885in general payments, 2019–2025

Across 644 payments — averaging $75.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$22K
  • Medtronic$9K
  • AbbVie$4K
  • Amneal Pharmaceuticals LLC$3K
  • MDD US Operations, LLC$3K
  • Avion Pharmaceuticals$2K
  • plus $7K from 42 others
$12,788in research payments, 2019–2025

Across 1 payment — averaging $12,788 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amneal Pharmaceuticals LLC$13K

What the payments were for

  • Consulting fees$11,81524%
  • Speaking & faculty fees$14,62030%
  • Grants$6,25013%
  • Travel & lodging$3,1847%
  • Food & beverage$12,92526%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,885 in reported general payments places this provider in the 85th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$69,802
Medicare patients
219
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine44$360,247
RytaryCarbidopa/Levodopa66$105,549
IngrezzaValbenazine Tosylate13$105,440
Nurtec OdtRimegepant Sulfate11$12,791
Carbidopa-LevodopaCarbidopa/Levodopa213$12,168
Rasagiline Mesylate35$7,640
Carbidopa-Levodopa ErCarbidopa/Levodopa62$3,079
Ropinirole ErRopinirole Hcl12$1,663
Primidone46$1,323
Donepezil Hcl58$926
Mirtazapine37$840
Midodrine Hcl18$796
Clonazepam58$552
Baclofen13$511
Propranolol Hcl ErPropranolol Hcl14$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$884$360,24744 claims
Amneal Pharmaceuticals LLCRytary$3,420$105,54966 claims
Neurocrine Biosciences, Inc.Ingrezza$21,846$105,44013 claims
PfizerNurtec Odt$66$12,79111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 506 neurology providers in Georgia.

Other neurology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →